Molecular Partners AG’s MOLN share price has surged by 9.28%, which has investors questioning if this is right time to sell.

March 13, 2025 NFL signs Novartis as first pharmaceutical partner-source The ... offers $3 billion worth of Novartis shares Emasan AG, an arm of the Sandoz Family Foundation, has launched a ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 13 and set a price target of ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The multi-year collaboration leverages Docquity's Awareness to Advocacy (A2A) Program to expand retinal health education amongst thousands of HCPs and widen access to retinal health products With 81.5 ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

Novartis’ oral Fabhalta (iptacopan) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...